Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ARTMS Products, Avectas, Avrobio, Bausch + Lomb, Berg, Boehringer Ingelheim, Chromadex, Cidara, Cortexyme, Donwha, Elasmogen, Erytech, Fortebio, Immunoprecise Antibodies, Intract, Magenta, Predictive Oncology, Onk, Promis, Proteogenix, Santhera, Sinovac, Soluble, Stada, Telix, Tetra, Trovagene, VBL, Xbrane.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Algernon, Alnylam, Amgen, Axcella, Eisai, Ferring, Galecto, Humanigen, Jounce, Lilly, Lineage Cell, Merck and Co., Mesoblast, Noxopharm, Nucana, Oncosec, Rebiotix, Rigel, Scholar Rock, Spero, Teva.

Biopharmas raising money in public or private financings, including: Aptose, Algernon, Delcath, Kura, Mind Medicine, Nascent, Oncology Venture, TG, Trillium.

Quarterly snapshots from biopharma companies with marketed products, including: Acorda, Alexion, Alnylam, Clovis, Exelixis, Horizon.

New hires and promotions in the biopharma industry, including: Anchiano, Biosig, Centogene, Immunocore, Janssen, Lodo, Mimedx, Respirerx, Schrodinger.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Tessa Therapeutics.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Aridis, Athersys, Biontech, Calcimedica, Chimerix, Cromos, Eiger, Eli Lilly, Geneone Life Science, Gilead Sciences, Gracell, I-Mab, Innate, Innovent, Inovio, Janssen, Lupin, Mesoblast, Morphosys, Novartis, Pfizer, R-Pharm, Synairgen, Yuhan.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Akarx, Algernon, Ascentage, Capricor, Combioxin, Cytodyn, Junshi, Moderna, Pharmamar, Remegen, Shionogi, Telix.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Affibody, Alnylam, Anixa, Aravive, Astellas, Astrazeneca, Atreca, Bausch + Lomb, Beigene, Bioage Labs, Biocon, Bixink, Catalent, Celltrion, Clearside, Cytodyn, Daewoong, Edigene, Eli Lilly, Evergreenhealth, Fujifilm Diosynth, Generex, Gilead, Harbour, Heat Biologics, IGM Biosciences, Inovio, Insilico, J&J, Junshi, Lonza, Marinomed, Moderna, Mylan, Nanoviricides, Noachis Terra, Ology, Ontochem, Oragenics, Oxford Biodynamics, Pneumagen, Proteogenix, Puma, Recce, Sarepta, Secarna, Shionogi, Stabilitech, Taisho, Takis, Teva, Union, Vaxart, Verndari, Vir, Viralclear, Vistagen, Wuxi, Xbiotech USA, Xortx.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Pluristem.